Dr. John Cush RheumNow
2 weeks 3 days ago
Challenges in Gout Diagnosis
Dr. Angelo Gaffo in Birmingham, AL discusses the challenges in diagnosing gout. Presented as part of RheumNow's "Gout: More than Flares" campaign during the month of July 2026.
https://t.co/LmTj7cvBGT https://t.co/VRVCrAo2TT
Dr. John Cush RheumNow
2 weeks 3 days ago
QD CLINIC: Senior Year Gout
Daric Mueller, PA-C, discusses a case of difficult-to-treat gout in an individual first diagnosed at age 18 who is now in his early 30s. This QD Clinic is presented as part of RheumNow's "Gout: More than Flares" campaign.
https://t.co/9GNk8ZqwyS https://t.co/hAFz6zPcay
In a recent JAMA Viewpoints article, Dr. Susan Ott addresses several controversies in preventing osteoporosis (OP) related fractures.
Dr. John Cush RheumNow
2 weeks 3 days ago
Weight loss helps gout, but extreme weight loss (bariatric surgery, ketogenic diets) may trigger gouty attacks. (Not seen with GLP-1 agonist weight loss)
For more gout content, follow our Gout: More than Flares campaign at https://t.co/xnBVBN5IXZ, https://t.co/LGEENexSZ6
Dr. John Cush RheumNow
2 weeks 3 days ago
Subanalysis of SURMOUNT-1 Obesity trial l (2539 pts w/ BMI ≥ 30; tirzepatide vs PBO) showed 21% wt loss by wk 72 w/ TIRZ. Serum uric acid (SUA) decr by -0.69, -0.92, & -0.95 mg/dL on TIRZ (5, 10, & 15 mg qd). Wt loss explained 73% of SUA reduction. https://t.co/V0stEDC4lF https://t.co/t8qNNCrrGM
Dr. John Cush RheumNow
2 weeks 3 days ago
NEJM Retracts Pivotal ADVOCATE Trial of FDA-Approved Avacopan
The New England Journal of Medicine (NEJM) retracted the pivotal study supporting FDA's approval of avacopan (Tavneos) for severe forms of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. https://t.co/GOVyk5poNq
Dr. John Cush RheumNow
2 weeks 3 days ago
DMARD Efficacy in RA-ILD
A network meta-analysis in the Journal of Autoimmunity reviews the pharmacologic options for rheumatoid arthritis–associated interstitial lung disease (RA-ILD). RA-ILD guidelines were recently presented by ERS/EULAR, but these were mainly conditional,
CAR-T therapy in autoimmune disease is moving fast - but is it ready to move beyond specialized referral centers? This EULAR 2026 recap covers the mechanistic data, relapse biology, and access innovations shaping that answer.
Dr. John Cush RheumNow
2 weeks 4 days ago
The Power of Self-Management with Chronic Low Back Pain
Almost everyone will deal with back pain at some point in their lives. Most recover quickly — but for about 20% of people, acute pain becomes a chronic condition that interferes with daily life and keeps them out of the https://t.co/urZPsVwCV8
Dr. John Cush RheumNow
2 weeks 4 days ago
Uric Acid: Is Lower Better?
There is good evidence that a serum urate less than 6 mg/dL is required to meaningfully reduce urate crystal and gout flare burden, but is even lower better and are there any tradeoffs?
https://t.co/yVZOuMhZmr https://t.co/Ldc1pBQThH
Dr. John Cush RheumNow
2 weeks 4 days ago
< 40% of gout patients are on ULT; <40% of ULT-treated gout patients achieve T2T (SUA < 6.0 mg/dl).
For more gout content, follow our Gout: More than Flares campaign at https://t.co/j3iLMZz4HM, https://t.co/zFTozS62me
Dr. John Cush RheumNow
2 weeks 4 days ago
How should imaging guide the diagnosis and management of gout?
Hear from Dr. Nicola Dalbeth, Dr. John Fitzgerald, and Dr. Sarah Tedeschi, moderated by Dr. Jack Cush, as they discuss ultrasound, DECT, crystal identification, and more.
📅 Reserve your seat today.
Link: https://t.co/GySPzyVc1b
Dr. John Cush RheumNow
2 weeks 4 days ago
Gout is more than an episodic arthritis, it's a systemic inflammatory disease.
Watch Dr. Robert Terkeltaub discuss 3 New Things it Pays to Know About Gout Pathobiology, including emerging insights that are shaping how we understand and manage gout.
Watch now on RheumNow: https://t.co/nri3WDz7kS

